Evidence map›Paper›PMID 33073719›Full record

ArticleTechnology in cancer research & treatment

Clinical features and diagnostic imaging of cholangiolocellular carcinoma compared with other primary liver cancers: a surgical perspective.

Hiroyuki Takamura, Ryousuke Gabata, Yoshinao Obatake, Shinichi Nakanuma, Hironori Hayashi, Kazuto Kozaka, Motoko Sasaki, Mitsuyoshi Okazaki, Takahisa Yamaguchi, Hiroyuki Shimbashi and 21 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 2 institutions in 1 country.

Hiroyuki TakamuraGeneral and Digestive Surgery, 12857Kanazawa Medical University, Kahoku, Ishikawa, Japan.ORCID 0000-0002-8824-6763
Ryousuke GabataGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Yoshinao ObatakeGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Shinichi NakanumaGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Hironori HayashiGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Kazuto KozakaRadiology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Motoko SasakiPathology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Mitsuyoshi OkazakiGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Takahisa YamaguchiGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Hiroyuki ShimbashiGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Shiro TeraiGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Koichi OkamotoGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Isamu MakinoGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Jun KinoshitaGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Keishi NakamuraGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Tomoharu MiyashitaGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Hidehiro TajimaGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Itasu NinomiyaGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Sachio FushidaGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Azusa KitaoRadiology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Masaaki KitaharaGastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Kuniaki AraiGastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Taro YamashitaGastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Tatsuya YamashitaGastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Hiroko IkedaPathology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Yasunori SatohPathology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Kenichi HaradaPathology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Syuichi KanekoGastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Toshihumi GabataRadiology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Tateo KosakaGeneral and Digestive Surgery, 12857Kanazawa Medical University, Kahoku, Ishikawa, Japan.
Tetsuo OhtaGastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.
Kanazawa University · JPKanazawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAlthough cholangiolocellular carcinoma is considered a combined hepatocellular and cholangiocarcinoma, we feel that this classification is not appropriate. Therefore, we compared the diagnostic imaging findings, surgical prognosis, and pathological features of cholangiolocellular carcinoma with those of other combined hepatocellular and cholangiocarcinoma subtypes, hepatocellular carcinoma, and cholangiocarcinoma.

methodsThe study patients included 7 with classical type combined hepatocellular and cholangiocarcinoma; 8 with stem cell feature, intermediate type combined hepatocellular and cholangiocarcinoma; 13 with cholangiolocellular carcinoma; 58 with cholangiocarcinoma; and 359 with hepatocellular carcinoma. All patients underwent hepatectomy or living-related donor liver transplantation from 2001 to 2014.

resultscholangiolocellular carcinoma could be distinguished from hepatocellular carcinom, other combined hepatocellular and cholangiocarcinoma subtypes, and cholangiocarcinoma by the presence of intratumoral Glisson's pedicle, hepatic vein penetration, and tumor-staining pattern on angiography-assisted CT. Cholangiolocellular carcinoma was associated with a significantly lower SUV-max than that of cholangiocarcinoma on FDG-PET. Hepatocellular carcinoma, classical type, and cholangiolocellular carcinoma had significantly better prognoses than stem cell feature, intermediate type and cholangiocarcinoma. A cholangiocarcinoma component was detected in cholangiolocellular carcinoma that progressed to the hepatic hilum, and the cholangiocarcinoma component was found in perineural invasion and lymph node metastases.

conclusionsFrom the viewpoint of surgeon, cholangiolocellular carcinoma should be classified as a good-prognosis subtype of biliary tract carcinoma because of its tendency to differentiate into cholangiocarcinoma during its progression, and its distinctive imaging and few recurrence rates different from other combined hepatocellular and cholangiocarcinoma subtypes.

Indexed as

AgedBiomarkers, TumorBiopsyCarcinoma, HepatocellularCholangiocarcinomaClinical Decision-MakingDiagnosis, DifferentialDiagnostic ImagingDisease ManagementFemaleHepatectomyHumansImmunohistochemistryLiver NeoplasmsMaleMiddle AgedBiomarkers, Tumorbile ductular carcinomacholangiolocarcinomacholangiolocellular carcinomacombined hepatocellular and cholangiocarcinoma

Identifiers

PMID33073719
PMCPMC7592326
OpenAlexW3092839783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.